Since TRAIL-R2 is a transcriptional target of p53 [26], anti-tumor therapy has also aimed at potentiating cell death in wild-type p53-expressing malignant cells by enhancing TRAIL-R2 expression at the plasma membrane [27–29]. This evidence concerns the gene TNFRSF10B and neoplasm.